Perspective Therapeutics (CATX) Net Margin (2010 - 2023)

Perspective Therapeutics (CATX) posted Net Margin of 105.73% for Q4 2023, up 394.67% sequentially from 35.88% in Q3 2023.

Perspective Therapeutics (CATX) Net Margin (2010 - 2023) Analysis & Trends

Perspective Therapeutics has reported Net Margin for 14 years, with the latest figure at 105.73% in Q4 2023.

Quarterly Net Margin changed N/A year-over-year to 105.73% in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 1070.09% (changed N/A YoY) and the FY2023 annual result came in at 631.31%, changed N/A from the prior year.
Net Margin grew to 105.73% in Q4 2023 per CATX's latest filing, from 35.88% in the prior quarter.
Over five years, Net Margin peaked at 105.73% in Q4 2023 and troughed at 108.0% in Q2 2023.
A 5-year average of 44.28% and a median of 40.75% in 2019 frame the typical range for Net Margin.
The sharpest annual moves came in 2019 and 2023: Net Margin surged 9022 bps in 2019, then slumped 6963 bps in 2023.
Over 5 years, Net Margin stood at 40.75% in 2019, then increased by 10 bps to 36.8% in 2020, then tumbled by 55 bps to 56.96% in 2021, then sank by 84 bps to 105.06% in 2022, then surged by 201 bps to 105.73% in 2023.
According to Business Quant data, Net Margin over the past three periods registered 105.73%, 35.88%, and 108.0% for Q4 2023, Q3 2023, and Q2 2023 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Abbott Laboratories	199.61 Bn	194.01 Bn	7.27 Bn	7.37%
2	Stryker	127.81 Bn	124.34 Bn	4.50 Bn	19.37%
3	Medtronic	119.04 Bn	109.82 Bn	6.41 Bn	12.84%
4	Boston Scientific	73.68 Bn	73.14 Bn	3.85 Bn	16.67%
5	Edwards Lifesciences	51.96 Bn	47.71 Bn	1.35 Bn	13.87%
6	Dexcom	34.36 Bn	32.41 Bn	830.00 Mn	19.04%
7	GE HealthCare Technologies	33.83 Bn	31.72 Bn	2.18 Bn	10.84%
8	Koninklijke Philips	26.36 Bn	23.04 Bn	4.55 Bn	6.47%
9	Steris	23.06 Bn	22.58 Bn	684.20 Mn	13.47%
10	Perspective Therapeutics	384.27 Mn	384.27 Mn	-	-

Download Data